ASCO 2024: Updates in Multiple Myeloma : Episode 3
Opinion
Video
MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
Dr Garfall, MD, provides further insights around the MajesTEC-1 study.
Video content above is prompted by the following:
- Please provide your key takeaways from this study. How do these updated results impact the potential use of teclistamab in the management of RRMM?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact treatment regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
December 26th 2024
